Tsenova Liana, Harbacheuski Ryhor, Sung Nackmoon, Ellison Evette, Fallows Dorothy, Kaplan Gilla
Laboratory of Mycobacterial Immunity and Pathogenesis, The Public Health Research Institute (PHRI), 225 Warren Street, Newark, NJ 07103, USA.
Vaccine. 2007 Jul 9;25(28):5126-32. doi: 10.1016/j.vaccine.2006.11.024. Epub 2006 Nov 27.
Using a rabbit model of tuberculous meningitis (TBM), we compared the protective efficacy of Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccination against central nervous system infection with the virulent M. tuberculosis clinical isolate HN878 and the laboratory strain H37Rv. Although BCG clearly provided protection against infection with either challenge strain, protection against disease manifestations was significantly poorer in rabbits infected with HN878. BCG was less efficient in protecting against HN878 dissemination to the liver and spleen and against HN878-induced inflammation, loss of body weight, lung and brain pathology, and signs of disease. We suggest that the efficacy of newly developed vaccines should be tested in animal models not only against challenge with M. tuberculosis H37Rv but also with different clinical isolates including the highly virulent strains of the W-Beijing family.
利用结核性脑膜炎(TBM)兔模型,我们比较了卡介苗(BCG)接种对中枢神经系统感染的保护效果,分别用强毒力结核分枝杆菌临床分离株HN878和实验室菌株H37Rv进行攻击。虽然卡介苗显然对两种攻击菌株的感染均提供了保护,但在感染HN878的兔子中,对疾病表现的保护明显较差。卡介苗在预防HN878扩散至肝脏和脾脏以及预防HN878诱导的炎症、体重减轻、肺和脑病理变化及疾病体征方面效果较差。我们建议,新开发疫苗的效果不仅应在动物模型中针对结核分枝杆菌H37Rv攻击进行测试,还应针对包括W-北京家族高毒力菌株在内的不同临床分离株进行测试。